MUMBAI, Nov 6 (Reuters) - India's Sun Pharmaceutical Industries Ltd (SUN.BO) said on Friday its unit secured approval from the U.S. Food and Drug Administration for generic Acular, used in treatment of ocular itching.
The drug is the therapeutic equivalent of Acular Ophthalmic solution Allergan, Inc. (AGN), it said in a statement to the BSE. (Reporting by Tamajit Pain; Editing by Sunil Nair)
© Thomson Reuters 2009 All rights reserved
Ohio's top lawyer is knee-deep in litigation against major financial giants. Calling it a "badge of honor" to hold Wall Street accountable for its actions. Richard Cordray is looking for a fight. Full Article | Full Coverage
Reuters.com:
Help and Contact Us |
Advertise With Us |
Mobile |
Newsletters |
RSS
|
Labs |
Journalism Handbook |
Archive |
Site Index |
Video Index
Thomson Reuters Corporate: Copyright | Disclaimer | Privacy | Professional Products | Professional Products Support | About Thomson Reuters | Careers
International Editions: Africa | Arabic | Argentina | Brazil | Canada | China | France | Germany | India | Italy | Japan | Latin America | Mexico | Russia | Spain | United Kingdom | United States
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
